- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Supernus, Inc (SUPN)
Supernus, Inc stock price live, this page displays NASDAQ SUPN stock exchange data. View the SUPN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Supernus, Inc real time stock price chart below.
What Is the Supernus, Inc Stock Price Today?
The Supernus, Inc stock price today is 29.72.
What Is the Stock Symbol for Supernus, Inc?
The stock symbol for Supernus, Inc is "SUPN."
What Stock Exchange Does Supernus, Inc Trade On?
Supernus, Inc is listed and trades on the NASDAQ stock exchange.
Is Supernus, Inc a Good Stock to Buy?
Determining whether Supernus, Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SUPN quote. (ISIN: US45579U1097)
What Is the Supernus, Inc Stock Price Today?
The Supernus, Inc stock price today is 29.72.
What Is the Stock Symbol for Supernus, Inc?
The stock symbol for Supernus, Inc is "SUPN."
What Stock Exchange Does Supernus, Inc Trade On?
Supernus, Inc is listed and trades on the NASDAQ stock exchange.
Is Supernus, Inc a Good Stock to Buy?
Determining whether Supernus, Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SUPN quote. (ISIN: US45579U1097)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.81
29.92
52 wk Range
21.48
33.22
High dividend Yield
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.8129.92
52 wk Range
21.4833.22
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SUPN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
54.14
Upside
+82.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 54.14
(+82.18% Upside)
Supernus, Inc Earnings Call Summary for Q2/2026
- Supernus and Indivior beat Q2 2026 estimates with EPS of $1.15 vs. $0.74 forecast and revenue of $343M vs. $284.9M, up 55.4% and 20.4% respectively.
- Companies announced all-stock merger creating CNS-focused drugmaker with $2.2B annual revenue, $888M adjusted EBITDA, and $125M expected cost synergies.
- Combined entity to maintain four sales forces across ADHD, Parkinson's, women's health, and addiction; merger expected to close Q4 2026 pending approvals.
- SUBLOCADE holds 76% share of long-acting injectable OUD market with record patient starts; Qelbree cited as fastest-growing ADHD brand driving momentum.
- Pro forma company shows 41% adjusted EBITDA margin with $878M net debt; Indivior shares down 1.22% to $39.52 despite strong results and strategic rationale.
Last Updated: 08/03/2026, 09:40 PM
Read Full TranscriptEarnings
Latest Release
Oct 29, 2026
EPS / Forecast
1.32 / 0.80
Revenue / Forecast
356M / 291.63M
Compare SUPN to Peers and Sector
Metrics to compare | SUPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSUPNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 13.7x | −6.2x | −0.2x | |
PEG Ratio | 0.05 | −0.10 | 0.00 | |
Price/Book | −102.9x | 1.8x | 2.6x | |
Price / LTM Sales | 4.5x | 4.0x | 2.8x | |
Upside (Analyst Target) | 82.2% | 50.6% | 65.0% | |
Fair Value Upside | Unlock | 5.3% | 9.6% | Unlock |
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026. Supernus, Inc. was incorporated in 2014 and is headquartered in Rockville, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Supernus, Inc (SUPN) Stock Price Today?
The Supernus, Inc stock price today is 29.72 USD.
What Stock Exchange Does Supernus, Inc Trade On?
Supernus, Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Supernus, Inc?
The stock symbol for Supernus, Inc is "SUPN."
Does Supernus, Inc Pay Dividends? What’s The Current Dividend Yield?
The Supernus, Inc dividend yield is 27.4%%.
What Is the Supernus, Inc Market Cap?
As of today, Supernus, Inc market cap is 6.07B USD.
What Is Supernus, Inc's Earnings Per Share (TTM)?
The Supernus, Inc EPS (TTM) is 3.69.
From a Technical Analysis Perspective, Is SUPN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Supernus, Inc Stock Split?
Supernus, Inc has split 0 times.
How Many Employees Does Supernus, Inc Have?
Supernus, Inc has 833 employees.
What is the current trading status of Supernus, Inc (SUPN)?
As of Nov 14, 2026, Supernus, Inc (SUPN) is trading at a price of 29.72 USD, with a previous close of 29.20 USD. The stock has fluctuated within a day range of 28.81 USD to 29.92 USD, while its 52-week range spans from 21.48 USD to 33.22 USD.
What Is Supernus, Inc (SUPN) Price Target According to Analysts?
The average 12-month price target for Supernus, Inc is 54.14 USD, with a high estimate of 87 USD and a low estimate of 45 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +82.18% Upside potential.
What Is the SUPN Premarket Price?
SUPN's last pre-market stock price is 29.40 USD. The pre-market share volume is 160.00, and the stock has decreased by 0.20, or 0.68%.
What Is the SUPN After Hours Price?
SUPN's last after hours stock price is 29.51 USD, the stock has decreased by -0.21, or -0.71%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.